Search research articles
Contact Us
Filters
Showing results (261-270 of 309) with videos related to
Page
of 31
Sort By:
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
NPJ Parkinson'S Disease
|
July 27, 2021
Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease
Luis M A Oliveira, Thomas Gasser, Robert Edwards, et al.
Cell Chemical Biology
|
August 10, 2022
Discovery of compounds that reactivate p53 mutants in vitro and in vivo
Geetha Durairaj, Özlem Demir, Bryant Lim, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Nature Genetics
|
March 14, 2023
Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis
Kevin Nee, Dennis Ma, Quy H Nguyen, et al.
Human Vaccines & Immunotherapeutics
|
May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials
Faye Yu, Eugene Myshkin, Brandon Nguyen, et al.
Page
of 31
Search research articles
Search
Showing results (261-270 of 309) with videos related to
Sort By:
Page
of 31
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
NPJ Parkinson'S Disease
|
July 27, 2021
Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease
Luis M A Oliveira, Thomas Gasser, Robert Edwards, et al.
Cell Chemical Biology
|
August 10, 2022
Discovery of compounds that reactivate p53 mutants in vitro and in vivo
Geetha Durairaj, Özlem Demir, Bryant Lim, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Nature Genetics
|
March 14, 2023
Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis
Kevin Nee, Dennis Ma, Quy H Nguyen, et al.
Human Vaccines & Immunotherapeutics
|
May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials
Faye Yu, Eugene Myshkin, Brandon Nguyen, et al.
Page
of 31